AR033989A1 - Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene - Google Patents

Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene

Info

Publication number
AR033989A1
AR033989A1 ARP010103541A ARP010103541A AR033989A1 AR 033989 A1 AR033989 A1 AR 033989A1 AR P010103541 A ARP010103541 A AR P010103541A AR P010103541 A ARP010103541 A AR P010103541A AR 033989 A1 AR033989 A1 AR 033989A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroalkyl
hydrogen
heterocyclyl
substituted
Prior art date
Application number
ARP010103541A
Other languages
English (en)
Inventor
Leyi Gong
Andrew Grupe
Gary Allen Peltz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR033989A1 publication Critical patent/AR033989A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de la 3-indolil-4-fenil-1h-pirrol-2,5-diona de Fórmula (I): donde R1 y R2 independientemente representan hidrógeno, alquilo, halógeno, haloalquilo, tioalquilo, hidroxi, alcoxi, ciano, nitro, amino, acilamino, monoalquilamino, o dialquiloamino; R3 representa hidrógeno, alquilo, cicloalquilo, heteroalquilo, -COR7 (donde R7 es hidrógeno o alquilo) o fenilo opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados del grupo consistente en hidrógeno, alquilo, haloalquilo, tioalquilo, hidroxi, alcoxi, ciano, nitro, amino, acilamino, monoalquilamino y dialquilamino; R4 y R5 independientemente representan hidrógeno, alquilo, halógeno, haloalquilo, tioalquilo, hidroxi, alcoxi, ciano, nitro, amino, acilamino, monalquilamino, o dialquilamino; R6 es heteroalquilo, heterocicillo, heterociclil alquilo, heterociclilo, heteralquilosustituido, cicloalquilo heteroalquilosustituido, cicloalquilo heterosustituido, -OR8, -S(O)nR8 (done n es un número entero del 0 al 2; y R8 es heteroalquilo, heteroaralquilo, heterociclilo, o heterociclilalquilo), -NR9R10 (donde R9 es hidrógeno o alquilo y R10 es cicloalquilo, heterosustituido, heteroalquilo, heteroaralquilo, heterociclilo, o heterociclilalquilo), o -X-(alquileno)-Y-Z (donde X es un enlace covalente, -O- -NH-, o -S(O)n1, - donde n1 es un número entero del 0 al 2, Y es -O-, -NH-, o -S- y Z es heteroalquilo o SiR11(R12)(R13) donde R11, R12 y R13 son independientemente hidrógeno o alquilo), o R6 junto con R4 forma un grupo metilendioxi o etilendioxi cuando éstos están adyacentes el uno del otro; o una sal farmacéuticamente aceptable de los mismos. Los compuestos son útiles como inhibidores de la glicógeno sintasa quinasa-3Beta, y por lo tanto, pueden ser utilizados para el tratamiento de las enfermedades mediadas por la GSK-3Beta. Un método para prepararlos y medicamentos que los contienen.
ARP010103541A 2000-07-27 2001-07-25 Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene AR033989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
AR033989A1 true AR033989A1 (es) 2004-01-21

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103541A AR033989A1 (es) 2000-07-27 2001-07-25 Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene

Country Status (32)

Country Link
US (2) US6479490B2 (es)
EP (1) EP1307447B1 (es)
JP (1) JP3984157B2 (es)
KR (1) KR20030017655A (es)
CN (1) CN1185229C (es)
AR (1) AR033989A1 (es)
AT (1) ATE284885T1 (es)
AU (1) AU2001293702A1 (es)
BR (1) BR0112965A (es)
CA (1) CA2417277A1 (es)
CZ (1) CZ2003555A3 (es)
DE (1) DE60107857T2 (es)
EC (1) ECSP034452A (es)
ES (1) ES2233691T3 (es)
GT (1) GT200100151A (es)
HK (1) HK1058670A1 (es)
HR (1) HRP20030030A2 (es)
HU (1) HUP0301431A2 (es)
IL (1) IL153851A0 (es)
JO (1) JO2293B1 (es)
MA (1) MA26936A1 (es)
MX (1) MXPA03000695A (es)
NO (1) NO20030328D0 (es)
NZ (1) NZ523462A (es)
PA (1) PA8523001A1 (es)
PE (1) PE20020338A1 (es)
PL (1) PL366701A1 (es)
RU (1) RU2003104796A (es)
UY (1) UY26857A1 (es)
WO (1) WO2002010158A2 (es)
YU (1) YU4403A (es)
ZA (1) ZA200300216B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6593600A (en) * 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
PL366009A1 (en) * 2000-10-02 2005-01-24 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
AU2002221810B2 (en) * 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
WO2003027069A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
DE60325551D1 (de) * 2002-01-10 2009-02-12 Hoffmann La Roche Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung
ATE346070T1 (de) 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren
EP1487822B1 (en) 2002-03-08 2007-08-01 Eli Lilly And Company Pyrrole-2,5-dione derivatives and their use as gsk-3 inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
CA2488602A1 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
WO2003103663A2 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
JP2007509185A (ja) * 2003-10-27 2007-04-12 ノバルティス アクチエンゲゼルシャフト βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
CN1949967B (zh) * 2004-05-12 2012-02-01 拜尔作物科学有限公司 植物生长调节作用
JP5289769B2 (ja) 2004-12-08 2013-09-11 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ ３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
JP4747364B2 (ja) 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
AU2009262241B2 (en) * 2008-06-25 2014-05-22 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
BR112013005689A2 (pt) * 2010-09-08 2016-05-03 Sumitomo Chemical Co método para produção de compostos de piridazinona e intermediário dos mesmos
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458A (zh) 2020-11-26 2021-03-23 北京赛尔湃腾科技咨询合伙企业(有限合伙) 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
WO1997022360A2 (en) 1995-12-20 1997-06-26 Medical Research Council Control of protein synthesis, and screening method for agents
AU2819397A (en) 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
HK1058670A1 (en) 2004-05-28
EP1307447B1 (en) 2004-12-15
HRP20030030A2 (en) 2005-02-28
KR20030017655A (ko) 2003-03-03
HUP0301431A2 (hu) 2003-08-28
CN1444581A (zh) 2003-09-24
PL366701A1 (en) 2005-02-07
UY26857A1 (es) 2002-01-31
ES2233691T3 (es) 2005-06-16
PA8523001A1 (es) 2002-10-24
DE60107857D1 (de) 2005-01-20
ATE284885T1 (de) 2005-01-15
WO2002010158A2 (en) 2002-02-07
JO2293B1 (en) 2005-09-12
IL153851A0 (en) 2003-07-31
CZ2003555A3 (en) 2004-03-17
JP3984157B2 (ja) 2007-10-03
WO2002010158A3 (en) 2002-05-16
NO20030328L (no) 2003-01-22
JP2004505078A (ja) 2004-02-19
US20020188018A1 (en) 2002-12-12
ECSP034452A (es) 2003-03-10
CA2417277A1 (en) 2002-02-07
DE60107857T2 (de) 2005-12-08
AU2001293702A1 (en) 2002-02-13
GT200100151A (es) 2002-05-23
MA26936A1 (fr) 2004-12-20
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
NO20030328D0 (no) 2003-01-22
PE20020338A1 (es) 2002-04-23
CN1185229C (zh) 2005-01-19
EP1307447A2 (en) 2003-05-07
ZA200300216B (en) 2004-04-08
US20020052397A1 (en) 2002-05-02
YU4403A (sh) 2006-05-25
US6479490B2 (en) 2002-11-12
MXPA03000695A (es) 2003-06-04
BR0112965A (pt) 2003-07-08

Similar Documents

Publication Publication Date Title
AR033989A1 (es) Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
CO6220933A2 (es) Formulaciones de dosis unitaria y metdods para el tratamiento de la trombosis con un inhibidor oral del facror xa
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
ES2422383T3 (es) Activadores de urea glucoquinasa
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
AR042572A1 (es) Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
AR038818A1 (es) Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
AR038276A1 (es) Metodos para incrementar la formacion osea.
BR0011282A (pt) Derivados da purina, seu processo de preparo e composiçoes farmacêuticas que as contêm
AR044830A1 (es) Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
EA200970364A1 (ru) Новые производные имидазолонов в качестве лекарственных средств, способ их получения, фармацевтические композиции и применение в качестве ингибиторов протеинкиназ, в частности, cdc7
AR036812A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes
EA200100090A3 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
AR013360A1 (es) Derivados de 6-azauracilo inhibidores de il-5, procedimiento para su preparacion, composicion que los contiene, procedimiento para preparardicha composicion, uso de dicho compuesto para la manufactura de medicamentos, de composiciones y procedimiento de marcado de un receptor.
BR0313734A (pt) Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
FA Abandonment or withdrawal